KROS - Keros Therapeutics Inc Stock Price, Fair Value and News

$14.07+0.54 (+3.99%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KROS Price Action

Last 7 days

15.0%

Last 30 days

24.0%

Last 90 days

29.6%

Trailing 12 Months

-76.3%

KROS RSI Chart

KROS Valuation

Market Cap

570.7M

Price/Earnings (Trailing)

-3.05

Price/Sales (Trailing)

24.29

EV/EBITDA

-0.06

Price/Free Cashflow

-3.51

KROS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KROS Fundamentals

KROS Revenue

Revenue (TTM)

23.5M

Rev. Growth (Yr)

73.56%

Rev. Growth (Qtr)

12.53%

KROS Earnings

Earnings (TTM)

-187.4M

Earnings Growth (Yr)

-14.37%

Earnings Growth (Qtr)

13.09%

KROS Profitability

EBT Margin

-796.11%

Return on Equity

-32.78%

Return on Assets

-30.42%

Free Cashflow Yield

-28.53%

KROS Investor Care

Shares Dilution (1Y)

12.73%

Diluted EPS (TTM)

-4.99

KROS Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.5M	18.8M	20.7M	23.5M
2023	6.4M	9.2M	12.0M	14.8M
2022	0	14.6M	9.1M	3.6M
2021	0	13.4M	16.7M	20.1M
2019	10.0M	10.0M	10.0M	10.0M
2018	0	0	0	10.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Jasbir S. Seehra Ph.D.
WEBSITE	kerostx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	121

Keros Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Keros Therapeutics Inc? What does KROS stand for in stocks?

KROS is the stock ticker symbol of Keros Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Keros Therapeutics Inc (KROS)?

As of Thu Apr 17 2025, market cap of Keros Therapeutics Inc is 570.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KROS stock?

You can check KROS's fair value in chart for subscribers.

Is Keros Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KROS is over valued or under valued. Whether Keros Therapeutics Inc is cheap or expensive depends on the assumptions which impact Keros Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KROS.

What is Keros Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, KROS's PE ratio (Price to Earnings) is -3.05 and Price to Sales (PS) ratio is 24.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KROS PE ratio will change depending on the future growth rate expectations of investors.